Hepatitis C Virus Data for Egyptian Patients with Treatment Response Metrics

Egyptian patients who underwent 18-month treatment dosages for Hepatitis C Virus (HCV). The dataset includes demographic, symptom, blood test, and liver enzyme measurements over time, collected for a predictive model of liver fibrosis. It was published by Mahmoud Nasr, Khaled El-Bahnasy, M. Hamdy, and S. Kamal in 2017.

Use Cases

• Predicting liver fibrosis based on non-invasive clinical and blood test features mentioned in the description.
• Analyzing the temporal response of alanine transaminase (ALT) and RNA levels to HCV treatment over an 18-month period.
• Modeling the relationship between baseline histological grading and patient demographic or symptomatic features.
• Identifying clinical markers associated with treatment outcomes for Hepatitis C in a specific geographic cohort.

Strengths

• Includes longitudinal measurements for key biomarkers (ALT, RNA) at multiple time points over an 18-month treatment period.
• Covers a range of data types: demographic (Age, Gender, BMI), symptomatic (Fever, Jaundice, Pain), and detailed blood test results (WBC, RBC, HGB, Plat, AST).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

OpenML, with original authors Nasr, M., El-Bahnasy, K., Hamdy, M., & Kamal, S. M.

Collection Method

Clinical records from Egyptian patients undergoing HCV treatment.

Time Range

Treatment period spans about 18 months.

Freshness

Last updated date is unknown.

Geography

Egypt